Slide 1: $1 Billion of Capital to Create the Global Leader in Premium Supplements
PRENETICS × GENERAL CATALYST · CUSTOMER VALUE FUND $1 Billion of Capital to Create the Global Leader in Premium Supplements Non-dilutive growth financing to accelerate IM8 to global category leadership
Slide 2: The world's fastest-growing supplement brand ever recorded
A NOTE FROM THE CEO The world's fastest-growing supplement brand ever recorded “ In just 19 months, we have become the world's fastest- $60M $210M–220M IM8 2025 FY revenue* Raised IM8 2026 FY revenue growing supplement brand ever recorded. With IM8, we guidance from $190M - $210M are building a mult
Slide 3: The Financial Case
WHY THIS DEAL CREATES VALUE FOR EVERY SHAREHOLDER · PART 1 OF 2 The Financial Case $1 billion of growth capital, with zero equity dilution Grows revenue and preserves cash, at the same time 1 2 $1 billion deployed to accelerate customer acquisition without issuing a single Traditional financing forc
Slide 4: The Strategic Case
WHY THIS DEAL CREATES VALUE FOR EVERY SHAREHOLDER · PART 2 OF 2 The Strategic Case The deepest external validation of our cohort economics Existing cash unlocked for higher-value strategic use 5 6 General Catalyst is the most sophisticated non-dilutive growth capital investor With customer acquisiti
Slide 5: How It Works and What It Costs
FINANCING STRUCTURE AND PAYBACK ECONOMICS How It Works and What It Costs Fund the month's customer growth, treated as a financial liability G C ' S P R E M I U M , B Y P A Y B A C K S P E E D ** 1 IM8's mature GC provides up to 70% of what IM8 elects to fund of its monthly marketing spend. That ≤ 3
Slide 6: IM8 Business Trajectory: Monthly Revenue Since Brand Inception
BUSINESS PERFORMANCE IM8 Business Trajectory: Monthly Revenue Since Brand Inception Monthly revenue grew ~42×, from $0.4M at launch to $17M, in 19 months, a ~23% compounded monthly growth rate, with strong momentum carrying into Q3 2026. $20M $16.8M $17.0M $15M $14.0M $11.8M $11.4M Monthly Revenue (
Slide 7: IM8 Cohort Payback: Cumulative Gross Profit / CAC
UNIT ECONOMICS IM8 Cohort Payback: Cumulative Gross Profit / CAC Q4 2024 (n=3,794 · CAC $217) Q1 2025 (n=27,074 · CAC $104) Q2 2025 (n=33,481 · CAC $139) Q3 2025 (n=57,617 · CAC $122) Q4 2025 (n=66,615 · CAC $189) Q1 2026 (n=59,955 · CAC $305) 4.0x 3.41x 3.0x 2.15x 2.22x 2.0x 1.70x 1.36x t on 1.0x 0
Slide 8: IM8 CAC vs New Subscriber AOV by Quarterly Vintage
UNIT ECONOMICS IM8 CAC vs New Subscriber AOV by Quarterly Vintage New Subscriber AOV (first-order value) Key insight: CAC grew 2.9x (Q1'25 → Q1'26) · New Subscriber AOV grew 2.5x · CAC/AOV improved: 1.15x (Q1'26) vs 1.18x (Q4'25) CAC (S&M spend ÷ new customers) value) 1.18x (Q4'25) WHY Q1'26 CAC STE
Slide 9: IM8 Cohort Detail: Customers, S&M, Revenue & Gross Profit by Quarterly Vintage
ACTUAL S&M SPEND vs GC FUNDING SIMULATION IM8 Cohort Detail: Customers, S&M, Revenue & Gross Profit by Quarterly Vintage GC @70% ($M) Cum Rev @M6 Cum GP @M6 Cohort New Customers S&M Spend ($M) CAC ($) GP/CAC @M6 Maturity Cum Rev ($M) Cum GP ($M) GP/CAC ($M) ($M) ($M) Q4 2024 3,794 $0.82 $217 $0.58 $
Slide 10: How GC's $1B Commitment Funds the Path to $1B ARR and Beyond
ILLUSTRATIVE — NOT FINANCIAL GUIDANCE USE OF CAPITAL How GC's $1B Commitment Funds the Path to $1B ARR and Beyond SPEND & GROWTH TO EVENTUALLY DECOUPLE Even as spend is deliberately held flat at the ~$60M/mo ceiling from 2028, the bars stop growing, but the revenue line keeps climbing. $300M $1500M
Slide 11: Prenetics × General Catalyst: Customer Value Fund Partnership
EXECUTIVE SUMMARY Prenetics × General Catalyst: Customer Value Fund Partnership $1 billion non-dilutive growth financing to accelerate IM8 to global category leadership $1B $210-$220M $400M+ General Catalyst Customer Value Fund commitment Increased FY 2026 IM8 revenue guidance Projected 2027 FY IM8
Slide 12: Significant Whitespace Ahead
$1B Revenue+ Significant Whitespace Ahead Modest Capture of the $200B+ Global Dietary Supplements Market Implies a $1B+ Brand Global Supplements Market Share: 0.5% Long-Term Vision Broaden $200M Rev+ Distribution Global Supplements Geographic Market Share: Penetration (Existing + New New 0.1% Market
Slide 13: Important information.
DISCLAIMER Important information. GENERAL FORWARD-LOOKING STATEMENTS This presentation has been prepared by Prenetics Global Limited (“Prenetics” or the “Company”) and is provided for This presentation contains forward-looking statements. These statements are made under the “safe harbor” provisions